ArticleSichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition2024
[Protective Effect of Ginsenoside Rg3 on Lipopolysaccharide-Induced Neuronal-Galial Interaction Injury Model].
Article in Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate the protective effect of ginsenoside Rg3 on lipopolysaccharide-induced galial-neuronal interaction injury model. Methods: Primary microglia cells and HT-22 cell lines were cultured, and the cells were divided into the control group (CON), the 100 ng/mL LPS group (LPS), the control inflammation model group (CM), the ginsenoside Rg3 group, and the inflammation model plus ginsenoside Rg3 treatment group (CM+Rg3). Ginsenoside Rg3 was administered in the ginsenoside Rg3 group and the CM+Rg3 group at the doses of 2.5, 5, 10, and 20 μmol/L. Galial-neuronal interaction modeling was performed in the CM group and the CM+Rg3 group. The purity of the primary microglia cells was assessed by immunofluorescence, the viability of the HT-22 cells in each group was assessed by CCK-8, and changes in the levels of inflammatory cytokines, including interleukin (IL)-1β, IL-6, tumor necrosis factor α (TNF-α), and IL-10, in the cell samples of each group were assessed with the ELISA kits. The level of cellular oxidative damage was measured with a ROS kit, and the expression of apoptosis-related proteins, including Bax and Bcl-2, was assessed by Western blot. The activity of Caspase-3 enzyme in each group was measured with a Caspase-3 enzyme activity kit. Results: The purity of the microglia cultured reached over 95% and was suitable for subsequent experiments. After ginsenoside Rg3 stimulation at different doses, the survival rate of HT-22 was not much different from that of the CON group. The survival rate of neurons after 100 ng/mL LPS stimulation was 98%, indicating that Rg3 and LPS had no effect on the survival of neurons. Compared with that of the CON group, the survival rate of HT-22 cells in the CM group was significantly decreased ( Conclusion: Ginsenoside Rg3 may play a role in the alleviation of neuronal apoptosis by regulating glial cell damage, reducing the secretion of inflammatory factors, and inhibiting neuronal apoptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.